Dowling & Yahnke’s Windtree Therapeutics Inc WINT Stock Holding History

Dowling & Yahnke’s Portfolio WINT Stock Details WINT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-20,003	Closed	-$4K	–	297
2017 Q3	$4K	Buy	+20,003	New	+$4K	﹤0.01%	281
2016 Q1	–	Sell	-5,004	Closed	-$15K	–	265
2015 Q4	$15K	Buy	+5,004	New	+$20.5K	﹤0.01%	252

Dowling & Yahnke's WINT Position: Q4 2017 in Review

Dowling & Yahnke sold out of Windtree Therapeutics Inc (WINT) in Q4 2017, closing a stake of 20,003 shares — an estimated $4K sold.

Dowling & Yahnke first reported a position in WINT in Q4 2015 and held it in 2 quarters. The position peaked at $15K in Q4 2015. 0 funds tracked by Wall St. Rank hold WINT as of Q4 2017.

Dowling & Yahnke reported no remaining Windtree Therapeutics Inc position as of Q4 2017 after selling out during the quarter.
Dowling & Yahnke sold 20,003 Windtree Therapeutics Inc shares in Q4 2017, an estimated $4K.
Dowling & Yahnke first reported a position in Windtree Therapeutics Inc in Q4 2015 and held it in 2 quarters.
Dowling & Yahnke's Windtree Therapeutics Inc position peaked at $15K in Q4 2015.
0 funds tracked by Wall St. Rank held Windtree Therapeutics Inc as of Q4 2017.

Based on Dowling & Yahnke's 13F filing for Q4 2017, filed 2 Feb 2018.